Bone Biologics Corp Stock Return On Asset
| BBLG Stock | USD 1.52 0.06 4.11% |
Bone Biologics Corp fundamentals help investors to digest information that contributes to Bone Biologics' financial success or failures. It also enables traders to predict the movement of Bone Stock. The fundamental analysis module provides a way to measure Bone Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bone Biologics stock.
Bone |
Bone Biologics Corp Company Return On Asset Analysis
Bone Biologics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Bone Biologics Return On Asset | -0.85 |
Most of Bone Biologics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bone Biologics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Bone Biologics Corp has a Return On Asset of -0.8454. This is 90.34% lower than that of the Health Care Equipment & Supplies sector and 95.33% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Bone Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bone Biologics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bone Biologics could also be used in its relative valuation, which is a method of valuing Bone Biologics by comparing valuation metrics of similar companies.Bone Biologics is currently under evaluation in return on asset category among related companies.
Bone Fundamentals
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.85 | ||||
| Current Valuation | (1.62 M) | ||||
| Shares Outstanding | 1.1 M | ||||
| Shares Owned By Insiders | 6.51 % | ||||
| Shares Owned By Institutions | 4.70 % | ||||
| Number Of Shares Shorted | 19.69 K | ||||
| Price To Earning | (15.45) X | ||||
| Price To Book | 0.51 X | ||||
| EBITDA | (9.43 M) | ||||
| Net Income | (8.95 M) | ||||
| Cash And Equivalents | 5.45 M | ||||
| Cash Per Share | 0.53 X | ||||
| Total Debt | 12.77 M | ||||
| Current Ratio | 80.11 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | (9.56 M) | ||||
| Short Ratio | 0.52 X | ||||
| Earnings Per Share | 19.88 X | ||||
| Target Price | 19.5 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 1.61 M | ||||
| Total Asset | 3.74 M | ||||
| Retained Earnings | (80.91 M) | ||||
| Working Capital | 2.91 M | ||||
| Current Asset | 1.07 M | ||||
| Current Liabilities | 2.16 M | ||||
| Net Asset | 3.74 M |
About Bone Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:Check out Bone Biologics Piotroski F Score and Bone Biologics Altman Z Score analysis. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Bone Stock analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Bone Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.